Advanced Medical Solutions Grp PLC CE Approval to market new product
September 02 2015 - 2:00AM
RNS Non-Regulatory
TIDMAMS
Advanced Medical Solutions Grp PLC
02 September 2015
02 September 2015
Advanced Medical Solutions Group PLC
("AMS" or the "Group")
CE Approval received for antimicrobial foam dressing
Winsford, UK, 01 September 2015 - Advanced Medical Solutions
Group plc (AIM: AMS.L), the surgical and advanced woundcare
specialist company, today announces that it has received CE
approval to market its Polyhexamethylene Biguanide (PHMB) non
adhesive antimicrobial foam dressing in Europe.
PHMB has been shown to be effective against several bacteria
including, amongst others, Staphylococcus Aureus including the
methicillin resistant type, (MRSA) and Escherichia Coli (E-Coli).
This antimicrobial foam wound dressing may be used throughout the
healing process on moderate to heavily exuding chronic and acute
wounds that are infected or are at risk of infection and may be
used on pressure ulcers, leg and foot ulcers, diabetic ulcers and
surgical wounds.
AMS expects to launch this product through its OEM partners in
2015, as well as including it in its ActivHeal(R) range of
woundcare dressings for the NHS.
Chris Meredith, Chief Executive Officer of AMS, commented: "We
are pleased to receive CE approval for this AMS product which
strengthens our position in the antimicrobial foam market and look
forward to launching it in EU markets and into the NHS later this
year."
- Ends -
For further information, please visit www.admedsol.com or
contact:
Advanced Medical Solutions Group Tel: +44 (0)
plc 1606 545508
Chris Meredith, Chief Executive
Officer
Mary Tavener, Group Finance Director
Consilium Strategic Communications Tel: +44 (0)
20 3709 5700
Mary-Jane Elliott / Jonathan
Birt / Matthew Neal / Hendrik
Thys
Investec Bank plc (NOMAD) & Broker Tel: +44 (0)
20 7597 5970
Gary Clarence / Daniel Adams
/ Patrick Robb
About Advanced Medical Solutions Group plc - see
www.admedsol.com
AMS is a world-leading independent developer and manufacturer of
innovative and technologically advanced products for the global
surgical, wound care and wound closure markets, focused on quality
outcomes for patients and value for payors. AMS has a wide range of
products that include silver alginates, alginates, foams, tissue
adhesives, sutures and haemostats, which it markets under its
brands ActivHeal(R) , LiquiBand(R) and RESORBA(R) as well as
supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in
the Netherlands, two in Germany and one in the Czech Republic, are
sold in 65 countries via a network of multinational or regional
partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia.
Established in 1991, the Group has approximately 470 employees. For
more information please see www.admedsol.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSUFWFFISESU
(END) Dow Jones Newswires
September 02, 2015 02:00 ET (06:00 GMT)
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Advanced Medical Solutions (LSE:AMS)
Historical Stock Chart
From Sep 2023 to Sep 2024